2023
Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine
Machavariani E, Bromberg D, Dumchev K, Dvoriak S, Zeziulin O, Morozova O, Esserman D, Pykalo I, Saichuk N, Ivasiy R, Haddad M, Altice F. Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine. Contemporary Clinical Trials 2023, 131: 107248. PMID: 37263492, PMCID: PMC10527419, DOI: 10.1016/j.cct.2023.107248.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyMajor depressive disorderCo-occurring disordersAgonist therapyDepressive disorderSpecialty clinicPsychiatric disordersPatient-level outcomesPrevalent psychiatric disordersCluster-randomized trialPoor health outcomesProvider-level dataMDD treatmentTreatment algorithmExperimental armHigh prevalenceDelivery outcomesHealth outcomesSerial surveysClinicPatientsProject ECHOSubstance useMonthsDisorders
2022
Implementation opportunities for scaling up methadone maintenance treatment in Kyrgyzstan: Methadone dosage and retention on treatment over two years
Ivasiy R, Madden LM, Farnum SO, Shumskaya N, de Leon S, Bromberg DJ, Kurmanalieva A, Duishenaliev A, Tokubaev R, Altice FL. Implementation opportunities for scaling up methadone maintenance treatment in Kyrgyzstan: Methadone dosage and retention on treatment over two years. Drug And Alcohol Dependence Reports 2022, 4: 100075. PMID: 36267100, PMCID: PMC9581459, DOI: 10.1016/j.dadr.2022.100075.Peer-Reviewed Original ResearchMethadone maintenance treatmentDosage levelsMaintenance treatmentCox multivariate regression modelMethadone dosage levelsProspective observational databaseNational treatment guidelinesProportion of patientsHigher dosage levelsOptimal dosageMMT retentionMMT patientsMethadone dosageTreatment guidelinesHIV statusMultivariate regression modelHigh doseSurvival analysisTreatment dropoutClinical settingCost-effective strategySignificant predictorsMonthsHIVObservational database
2021
Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationRelease
2018
The Influence of Housing Status on the HIV Continuum of Care: Results From a Multisite Study of Patient Navigation Models to Build a Medical Home for People Living With HIV Experiencing Homelessness
Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The Influence of Housing Status on the HIV Continuum of Care: Results From a Multisite Study of Patient Navigation Models to Build a Medical Home for People Living With HIV Experiencing Homelessness. American Journal Of Public Health 2018, 108: s539-s545. PMID: 32941777, PMCID: PMC6290582, DOI: 10.2105/ajph.2018.304736.Peer-Reviewed Original ResearchPatient navigation modelViral suppressionHIV outcomesHousing statusCo-occurring substance useAntiretroviral therapy prescriptionHigh rateAntiretroviral therapyChart reviewHIV continuumPatient navigatorsTherapy prescriptionMedical homePsychiatric disordersSubstance useMultisite studyHIVStable housingOutcomesCareMonthsHousing stabilityInterventionStatusNetwork of servicesExtended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2013
Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru
Vagenas P, Ludford KT, Gonzales P, Peinado J, Cabezas C, Gonzales F, Lama JR, Sanchez J, Altice FL, for the Peruvian HIV Sentinel Surveillance Working Group. Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. AIDS And Behavior 2013, 18: 120-127. PMID: 23670711, PMCID: PMC3796203, DOI: 10.1007/s10461-013-0504-2.Peer-Reviewed Original ResearchConceptsAlcohol use disorderHigh-risk sexual behaviorHIV infectionUse disordersMultivariate logistic regressionUnprotected anal intercourseSexual behaviorHIV-InfectedHIV statusSyphilis testingHIV riskAnal intercourseTherapy interventionHIVLogistic regressionMenLast encounterSexInfectionDisordersParticipantsRisk assessmentMSMPeruvian citiesMonthsMethadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug And Alcohol Dependence 2013, 132: 378-382. PMID: 23414931, PMCID: PMC3718876, DOI: 10.1016/j.drugalcdep.2013.01.005.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentMethadone doseKaplan-Meier survival analysisDose escalation procedureMethadone initiationThirty HIVMMT clinicsEvaluable participantsMaintenance treatmentOpioid dependenceMMT programSide effectsHigh dosesSurvival analysisHIVFirst weekPilot studyDoseMonthsTreatmentEscalation procedureDosesCravingParticipantsMonths of release
2011
Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s83-s90. PMID: 21317600, PMCID: PMC3066190, DOI: 10.1097/qai.0b013e31820bc9a5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineBuprenorphine, Naloxone Drug CombinationCohort StudiesFemaleGuideline AdherenceHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPractice Guidelines as TopicQuality of Health CareConceptsBUP/NXHIV careOpioid dependenceHIV qualitySummary quality scoresCare indicatorsBuprenorphine/naloxone maintenance therapyHigh-quality HIV careOpioid-dependent HIVRole of buprenorphineObservational cohort studyOpioid-dependent patientsQuality scoresNondependent patientsHIV clinicMaintenance therapyCohort studyBuprenorphine treatmentClinical outcomesMultivariable analysisMedical recordsPatientsCareMonthsHIV
2010
Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia
Choi P, Kavasery R, Desai MM, Govindasamy S, Kamarulzaman A, Altice FL. Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. International Journal Of STD & AIDS 2010, 21: 416-423. PMID: 20606222, PMCID: PMC2925151, DOI: 10.1258/ijsa.2009.009180.Peer-Reviewed Original Research